PNC Financial Services Group
CLDX icon

PNC Financial Services Group’s Celldex Therapeutics CLDX Stock Holding History

PNC Financial Services Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Sell
469
-16
-3% -$517 ﹤0.01% 3842
2026
Q1 		$15.4K Sell
485
-50
-9% -$1.36K ﹤0.01% 3797
2025
Q4 		$14.5K Sell
535
-21
-4% -$553 ﹤0.01% 3803
2025
Q3 		$14.4K Buy
556
+292
+111% +$6.77K ﹤0.01% 3781
2025
Q2 		$5.37K Buy
264
+165
+167% +$3.21K ﹤0.01% 4102
2025
Q1 		$1.8K Buy
99
+92
+1,314% +$2.06K ﹤0.01% 4377
2024
Q4 		$177 Sell
7
-238
-97% -$6.47K ﹤0.01% 4659
2024
Q3 		$8.33K Sell
245
-186
-43% -$7.09K ﹤0.01% 3860
2024
Q2 		$16K Buy
431
+39
+10% +$1.47K ﹤0.01% 3582
2024
Q1 		$16.5K Sell
392
-33
-8% -$1.35K ﹤0.01% 3547
2023
Q4 		$16.9K Buy
425
+33
+8% +$971 ﹤0.01% 3526
2023
Q3 		$10.8K Sell
392
-388
-50% -$12.2K ﹤0.01% 3726
2023
Q2 		$26.5K Buy
780
+296
+61% +$9.98K ﹤0.01% 3411
2023
Q1 		$17.4K Hold
484
– – ﹤0.01% 3562
2022
Q4 		$21.6K Buy
484
+397
+456% +$14.2K ﹤0.01% 3428
2022
Q3 		$2K Sell
87
-13
-13% -$399 ﹤0.01% 4164
2022
Q2 		$3K Buy
+100
New +$2.9K ﹤0.01% 4103
2021
Q1 		– Sell
-1,000
Closed -$18K – 4114
2020
Q4 		$18K Hold
1,000
– – ﹤0.01% 3378
2020
Q3 		$15K Buy
+1,000
New +$11.7K ﹤0.01% 3346
2019
Q4 		– Sell
-79
Closed – – 3998
2019
Q3 		$0 Hold
79
– – ﹤0.01% 3998
2019
Q2 		$0 Hold
79
– – ﹤0.01% 4023
2019
Q1 		$0 Sell
79
-1
-1% -$5 ﹤0.01% 4039
2018
Q4 		$0 Hold
80
– – ﹤0.01% 4052
2018
Q3 		$1K Hold
80
– – ﹤0.01% 4020
2018
Q2 		$1K Hold
80
– – ﹤0.01% 4044
2018
Q1 		$3K Hold
80
– – ﹤0.01% 3976
2017
Q4 		$3K Sell
80
-67
-46% -$2.87K ﹤0.01% 3940
2017
Q3 		$6K Hold
147
– – ﹤0.01% 3815
2017
Q2 		$5K Hold
147
– – ﹤0.01% 3797
2017
Q1 		$8K Sell
147
-53
-27% -$2.76K ﹤0.01% 3598
2016
Q4 		$11K Sell
200
-967
-83% -$55K ﹤0.01% 3448
2016
Q3 		$71K Sell
1,167
-36
-3% -$2.24K ﹤0.01% 2648
2016
Q2 		$79K Sell
1,203
-28
-2% -$1.78K ﹤0.01% 2607
2016
Q1 		$70K Buy
1,231
+333
+37% +$37.5K ﹤0.01% 2664
2015
Q4 		$211K Buy
898
+75
+9% +$16.4K ﹤0.01% 2051
2015
Q3 		$130K Sell
823
-52
-6% -$14.7K ﹤0.01% 2364
2015
Q2 		$331K Buy
875
+18
+2% +$7.15K ﹤0.01% 1884
2015
Q1 		$358K Buy
857
+7
+0.8% +$2.5K ﹤0.01% 1860
2014
Q4 		$233K Buy
850
+17
+2% +$4.23K ﹤0.01% 1982
2014
Q3 		$162K Hold
833
– – ﹤0.01% 2112
2014
Q2 		$204K Buy
833
+66
+9% +$14.9K ﹤0.01% 1904
2014
Q1 		$203K Hold
767
– – ﹤0.01% 1889
2013
Q4 		$278K Hold
767
– – ﹤0.01% 1702
2013
Q3 		$407K Buy
767
+534
+229% +$183K ﹤0.01% 1471
2013
Q2 		$55K Buy
+233
New +$45.9K ﹤0.01% 2352

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

PNC Financial Services Group's CLDX Position: Q2 2026 in Review

PNC Financial Services Group reduced its Celldex Therapeutics (CLDX) stake by 3.3% in Q2 2026, selling an estimated $517 and leaving 469 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3842.

PNC Financial Services Group first reported a position in CLDX in Q2 2013 and has held it in 45 quarters since. The position peaked at $407K in Q3 2013. 78 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • PNC Financial Services Group held 469 shares of Celldex Therapeutics worth $17.5K as of Q2 2026.
  • PNC Financial Services Group sold 16 Celldex Therapeutics shares in Q2 2026, an estimated $517.
  • Celldex Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3842 holding.
  • PNC Financial Services Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • PNC Financial Services Group's Celldex Therapeutics position peaked at $407K in Q3 2013.
  • 78 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.